Drug Detail

Information about Imatinib + Ipilimumab

Generic Name
IND
Imatinib + Ipilimumab
Brand Name (US)
Manufacturer
Novartis + Bristol Myers-Squibb
Drug Type
Tyrosine Kinase Inhibitor and Monoclonal antibody
Delivery
Oral + Intravenous
Approval Status
Both are approved. This combination is not approved for GIST. It is being evaluated in a phase 1 trial for GIST.
Indications
Overall Strategy
KIT Protein and immune system
Strategy
Block KIT + Stimulate the immune system
Drug Category
KIT/PDGFRA inhibitor + CTLA4 inhibitor


Links


Trials of this drug

  

Ipilimumab and Imatinib Mesylate in Advanced Cancer
   

Trial results


Search for this drug/combination in:

ClinicalTrials.gov

ASCO

Pubmed